I is reported that oral treatment with escin diminished behavioural impairments, oxidative stress and inflammation in the chronic MPTP/probenecid mouse model of Parkinson’s disease (PD) by reducing the levels of TNF-α, IL-6, IL-4, IL-10, SOD and catalase [86]. This evidence concerns the gene IL6 and Parkinson disease.